DE19857609A1 - Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen - Google Patents
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des MenschenInfo
- Publication number
- DE19857609A1 DE19857609A1 DE19857609A DE19857609A DE19857609A1 DE 19857609 A1 DE19857609 A1 DE 19857609A1 DE 19857609 A DE19857609 A DE 19857609A DE 19857609 A DE19857609 A DE 19857609A DE 19857609 A1 DE19857609 A1 DE 19857609A1
- Authority
- DE
- Germany
- Prior art keywords
- erythropoietin
- treatment
- cerebral
- cerebral ischemia
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 41
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 41
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 41
- 206010008120 Cerebral ischaemia Diseases 0.000 title claims abstract description 10
- 206010008118 cerebral infarction Diseases 0.000 title claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title abstract description 7
- 208000006011 Stroke Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 abstract description 7
- 230000000302 ischemic effect Effects 0.000 abstract description 6
- 230000001681 protective effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Priority Applications (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857609A DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| DE59907752T DE59907752D1 (de) | 1998-12-14 | 1999-12-13 | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
| NZ541591A NZ541591A (en) | 1998-12-14 | 1999-12-13 | Method for the treatment of cerebral ischaemia and use of erythropodietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| IL14357999A IL143579A0 (en) | 1998-12-14 | 1999-12-13 | Erythropoietin derivatives for the treatment of cerebral ischemia |
| PL349335A PL202483B1 (pl) | 1998-12-14 | 1999-12-13 | Zastosowanie erytropoetyny w leczeniu udaru |
| DK99966958T DK1140139T4 (da) | 1998-12-14 | 1999-12-13 | Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier |
| IDW00200101535A ID29107A (id) | 1998-12-14 | 1999-12-13 | Metoda pengobatan iskemia serebral dan penggunaannya eritropoetin atau turunan eritropoetin untuk penggunaan iskemia serebral |
| AU22831/00A AU766216C (en) | 1998-12-14 | 1999-12-13 | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| CA2353553A CA2353553C (en) | 1998-12-14 | 1999-12-13 | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| HU0104709A HUP0104709A3 (en) | 1998-12-14 | 1999-12-13 | Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia |
| HK02104485.2A HK1042655B (zh) | 1998-12-14 | 1999-12-13 | 促紅細胞生成素用於生產腦局部缺血藥物的應用 |
| EP99966958A EP1140139B2 (de) | 1998-12-14 | 1999-12-13 | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
| US09/868,089 US7514072B1 (en) | 1998-12-14 | 1999-12-13 | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| CNB998160474A CN1187085C (zh) | 1998-12-14 | 1999-12-13 | 促红细胞生成素用于生产脑局部缺血药物的应用 |
| BR9916197-4A BR9916197A (pt) | 1998-12-14 | 1999-12-13 | Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral |
| MXPA01005971A MXPA01005971A (es) | 1998-12-14 | 1999-12-13 | Metodo para el tratamiento de la isquemia cerebral y el uso de la eritropoyetina o derivados de la eritropoyetina para el tratamiento de la isquemia cerebral. |
| AT99966958T ATE253932T1 (de) | 1998-12-14 | 1999-12-13 | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
| ROA200100684A RO121409B1 (ro) | 1998-12-14 | 1999-12-13 | Utilizarea eritropoietinei sau a derivaţilor de eritropoietină, pentru tratamentul ischemiei cerebrale |
| ES99966958T ES2211218T5 (es) | 1998-12-14 | 1999-12-13 | Uso de eritropoyetina o derivados de eritropoyetina para tratar isquemias cerebrales. |
| PT99966958T PT1140139E (pt) | 1998-12-14 | 1999-12-13 | Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral |
| PCT/EP1999/009864 WO2000035475A2 (de) | 1998-12-14 | 1999-12-13 | Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
| RU2001116077/14A RU2242991C2 (ru) | 1998-12-14 | 1999-12-13 | Способ лечения церебральных ишемий, а также применение эритропоэтина или производных эритропоэтина для лечения церебральных ишемий |
| KR1020017007421A KR100774827B1 (ko) | 1998-12-14 | 1999-12-13 | 뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도 |
| JP2000587794A JP4750947B2 (ja) | 1998-12-14 | 1999-12-13 | 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 |
| IL143579A IL143579A (en) | 1998-12-14 | 2001-06-05 | Erythropoietin history to treat local anemia of the brain |
| ZA200104626A ZA200104626B (en) | 1998-12-14 | 2001-06-06 | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for treatment of cerebral ischaemia. |
| BG105575A BG65417B1 (bg) | 1998-12-14 | 2001-06-07 | Приложение на еритропоетин или еритропоетинови производни за лечение на мозъчни исхемии |
| NO20012896A NO330079B1 (no) | 1998-12-14 | 2001-06-12 | Anvendelse av erytropoietin for fremstilling av et legemiddel |
| JP2010283105A JP2011079860A (ja) | 1998-12-14 | 2010-12-20 | 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857609A DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19857609A1 true DE19857609A1 (de) | 2000-06-15 |
Family
ID=7891015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19857609A Ceased DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| DE59907752T Expired - Lifetime DE59907752D1 (de) | 1998-12-14 | 1999-12-13 | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59907752T Expired - Lifetime DE59907752D1 (de) | 1998-12-14 | 1999-12-13 | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7514072B1 (enExample) |
| EP (1) | EP1140139B2 (enExample) |
| JP (2) | JP4750947B2 (enExample) |
| KR (1) | KR100774827B1 (enExample) |
| CN (1) | CN1187085C (enExample) |
| AT (1) | ATE253932T1 (enExample) |
| AU (1) | AU766216C (enExample) |
| BG (1) | BG65417B1 (enExample) |
| BR (1) | BR9916197A (enExample) |
| CA (1) | CA2353553C (enExample) |
| DE (2) | DE19857609A1 (enExample) |
| DK (1) | DK1140139T4 (enExample) |
| ES (1) | ES2211218T5 (enExample) |
| HK (1) | HK1042655B (enExample) |
| HU (1) | HUP0104709A3 (enExample) |
| ID (1) | ID29107A (enExample) |
| IL (2) | IL143579A0 (enExample) |
| MX (1) | MXPA01005971A (enExample) |
| NO (1) | NO330079B1 (enExample) |
| NZ (1) | NZ541591A (enExample) |
| PL (1) | PL202483B1 (enExample) |
| PT (1) | PT1140139E (enExample) |
| RO (1) | RO121409B1 (enExample) |
| RU (1) | RU2242991C2 (enExample) |
| WO (1) | WO2000035475A2 (enExample) |
| ZA (1) | ZA200104626B (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020031A3 (de) * | 2000-09-04 | 2002-08-01 | Hannelore Ehrenreich | Verfahren von erythropoietin sowie dessen derivate zur behandlung von schizophrenie und verwandten psychosen |
| WO2003090665A3 (de) * | 2002-04-26 | 2004-01-08 | Florian Lang | Regulation der erythrozyten-apoptose |
| US7439063B2 (en) * | 2002-06-11 | 2008-10-21 | Burnham Institute For Medical Research | Neuroprotective synergy of erythropoietin and insulin-like growth factors |
| US7514072B1 (en) | 1998-12-14 | 2009-04-07 | Hannelore Ehrenreich | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| US7645733B2 (en) | 2003-09-29 | 2010-01-12 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| US7745387B2 (en) | 2002-07-26 | 2010-06-29 | Epoplus Gmbh & Co. Kg | Use of erythropoietin |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US8404226B2 (en) | 2002-07-03 | 2013-03-26 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| TR200103785T2 (tr) * | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US7048934B2 (en) | 2001-08-30 | 2006-05-23 | Stem Cell Therapeutics Inc. | Combined regulation of neural cell production |
| ES2383169T3 (es) * | 2001-09-14 | 2012-06-18 | Stem Cell Therapeutics Inc. | Aumento del número de células madre neurales inducido por prolactina y uso terapéutico del mismo |
| EP1633383A4 (en) * | 2003-03-27 | 2008-05-21 | Janssen Pharmaceutica Nv | USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| PL1675573T4 (pl) * | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
| WO2005077404A1 (en) * | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
| EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| AU2006297041A1 (en) | 2005-09-27 | 2007-04-05 | Stem Cell Therapeutics Corp. | Oligodendrocyte precursor cell proliferation regulated by prolactin |
| US8333974B2 (en) * | 2006-03-17 | 2012-12-18 | Stem Cell Therapeutics Corp. | Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents |
| WO2007142288A1 (ja) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | エリスロポエチンを用いた虚血性疾患の治療 |
| NO2170279T3 (enExample) | 2007-07-31 | 2018-05-26 | ||
| RU2446834C2 (ru) * | 2010-06-15 | 2012-04-10 | Елена Александровна Лебедева | Способ лечения пострадавших с сочетанной черепно-мозговой травмой |
| WO2012148200A2 (ko) | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
| RU2495688C1 (ru) * | 2012-03-28 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" | Способ лечения ишемии головного мозга в эксперименте |
| US9610444B2 (en) | 2013-03-15 | 2017-04-04 | Pacesetter, Inc. | Erythropoeitin production by electrical stimulation |
| KR20190052855A (ko) | 2017-11-09 | 2019-05-17 | 대한제당 주식회사 | 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
| RU2128227C1 (ru) | 1989-12-22 | 1999-03-27 | Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) | Способ активации транскрипционно-молчащего гена |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| JP3537151B2 (ja) * | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| RU2068268C1 (ru) * | 1992-03-19 | 1996-10-27 | Учебно-научный центр Медицинского центра при Правительстве РФ | Способ профилактики церебро-васкулярных заболеваний |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| FI955128L (fi) | 1993-04-29 | 1995-10-27 | Abbott Lab | Erytropoietiinianalogikoostumuksia ja menetelmä niiden valmistamiseksi ja käyttämiseksi |
| IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
| SE520730C2 (sv) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| TR200103785T2 (tr) | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
-
1998
- 1998-12-14 DE DE19857609A patent/DE19857609A1/de not_active Ceased
-
1999
- 1999-12-13 IL IL14357999A patent/IL143579A0/xx active IP Right Grant
- 1999-12-13 HU HU0104709A patent/HUP0104709A3/hu unknown
- 1999-12-13 DE DE59907752T patent/DE59907752D1/de not_active Expired - Lifetime
- 1999-12-13 PL PL349335A patent/PL202483B1/pl not_active IP Right Cessation
- 1999-12-13 BR BR9916197-4A patent/BR9916197A/pt not_active Application Discontinuation
- 1999-12-13 AT AT99966958T patent/ATE253932T1/de active
- 1999-12-13 ES ES99966958T patent/ES2211218T5/es not_active Expired - Lifetime
- 1999-12-13 JP JP2000587794A patent/JP4750947B2/ja not_active Expired - Fee Related
- 1999-12-13 RU RU2001116077/14A patent/RU2242991C2/ru not_active IP Right Cessation
- 1999-12-13 PT PT99966958T patent/PT1140139E/pt unknown
- 1999-12-13 CN CNB998160474A patent/CN1187085C/zh not_active Expired - Fee Related
- 1999-12-13 HK HK02104485.2A patent/HK1042655B/zh not_active IP Right Cessation
- 1999-12-13 KR KR1020017007421A patent/KR100774827B1/ko not_active Expired - Fee Related
- 1999-12-13 MX MXPA01005971A patent/MXPA01005971A/es active IP Right Grant
- 1999-12-13 DK DK99966958T patent/DK1140139T4/da active
- 1999-12-13 CA CA2353553A patent/CA2353553C/en not_active Expired - Fee Related
- 1999-12-13 US US09/868,089 patent/US7514072B1/en not_active Expired - Fee Related
- 1999-12-13 EP EP99966958A patent/EP1140139B2/de not_active Expired - Lifetime
- 1999-12-13 ID IDW00200101535A patent/ID29107A/id unknown
- 1999-12-13 RO ROA200100684A patent/RO121409B1/ro unknown
- 1999-12-13 WO PCT/EP1999/009864 patent/WO2000035475A2/de not_active Ceased
- 1999-12-13 AU AU22831/00A patent/AU766216C/en not_active Ceased
- 1999-12-13 NZ NZ541591A patent/NZ541591A/en not_active IP Right Cessation
-
2001
- 2001-06-05 IL IL143579A patent/IL143579A/en not_active IP Right Cessation
- 2001-06-06 ZA ZA200104626A patent/ZA200104626B/en unknown
- 2001-06-07 BG BG105575A patent/BG65417B1/bg unknown
- 2001-06-12 NO NO20012896A patent/NO330079B1/no not_active IP Right Cessation
-
2010
- 2010-12-20 JP JP2010283105A patent/JP2011079860A/ja not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| DEL MASTRO, L., VENTURINI, M.: Strategies for the use of epoietin alfa in breast cancer patients. In: Oncologist, 1998, 3/5, S. 314-318 in Form des EMBASE-Abstracts 1999359165 * |
| SAKANAKA, M., WEN, T.C. u.a.: In vivo evidence that erythropoietin protects neurons from ische- mic damage. In: Proceedings of the National Aca- demy of Sciences of the United States of America, 1998, Vol. 95, No. 8, S. 4635-40 in Form des MEDLINE-Abstracts 1998208593 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514072B1 (en) | 1998-12-14 | 2009-04-07 | Hannelore Ehrenreich | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| WO2002020031A3 (de) * | 2000-09-04 | 2002-08-01 | Hannelore Ehrenreich | Verfahren von erythropoietin sowie dessen derivate zur behandlung von schizophrenie und verwandten psychosen |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| WO2003090665A3 (de) * | 2002-04-26 | 2004-01-08 | Florian Lang | Regulation der erythrozyten-apoptose |
| US7439063B2 (en) * | 2002-06-11 | 2008-10-21 | Burnham Institute For Medical Research | Neuroprotective synergy of erythropoietin and insulin-like growth factors |
| US8404226B2 (en) | 2002-07-03 | 2013-03-26 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7745387B2 (en) | 2002-07-26 | 2010-06-29 | Epoplus Gmbh & Co. Kg | Use of erythropoietin |
| US7645733B2 (en) | 2003-09-29 | 2010-01-12 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19857609A1 (de) | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen | |
| DE69900249T2 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
| DD288094A5 (de) | Verwendung von gamma-interferon zur behandlung von gefaessverengungen | |
| DE4214953A1 (de) | Arzneimittel zur Erhöhung des Testosteronspiegels | |
| EP0331014A2 (de) | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe | |
| DE69818809T2 (de) | Verfahren zur behandlung von narbengewebe | |
| EP1528922B1 (de) | Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose | |
| DE3633651C2 (enExample) | ||
| DE10043457A1 (de) | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen | |
| EP0411395A2 (de) | Verwendung von ACE-Inhibitoren für die Atheroskleroseprophylaxe | |
| AT402691B (de) | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome | |
| EP2195014B1 (de) | Verwendung von g-csf für die behandlung von schlaganfall | |
| EP0523591A2 (de) | Verwendung eines Kava-Extraktes und seiner Inhaltsstoffe | |
| EP0788355B1 (de) | Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten | |
| DE10319837A1 (de) | Verwendung von Edelgasen, insbesondere Argon oder Xenon, zur Prophylaxe oder Therapie von Innenohrerkrankungen | |
| WO1999056735A2 (de) | Verwendung von antioxidantien zur behandlung von entzündlichen hauterkrankungen | |
| DE19516773A1 (de) | Verwendung von DNA zur Herstellung von Arzneimitteln | |
| DE4010529A1 (de) | Verwendung von mindestens einem cytokin enthaltenden arzneimitteln zur systemischen behandlung von praeneoplastischen laesionen | |
| DE102007040932A1 (de) | Flüssigformulierung von G-CSF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8143 | Lapsed due to claiming internal priority | ||
| 8170 | Reinstatement of the former position | ||
| 8131 | Rejection |